Free Trial
→ A new type of AI could unleash gains of up to 10,000% (From Brownstone Research) (Ad)tc pixel
NASDAQ:QCLS

Mymd Pharmaceuticals Q4 2025 Earnings Report

Mymd Pharmaceuticals logo
$0.75 -0.03 (-3.52%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$0.74 -0.01 (-1.07%)
As of 10/2/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Mymd Pharmaceuticals EPS Results

Actual EPS
$6.11
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mymd Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mymd Pharmaceuticals Announcement Details

Quarter
Q4 2025
Date
4/15/2026
Time
After Market Closes
Conference Call Date
Wednesday, April 15, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

Mymd Pharmaceuticals Earnings Headlines

Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab
October 1 at 1:47 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373314/0/en/q-c-technologies-announces-research-collaboration-with-sandia-national-laboratories-a-5-billion-u-s-department-of-energy-lab.html
Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab
September 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3371894/0/en/q-c-technologies-announces-research-collaboration-with-sandia-national-laboratories-a-5-billion-u-s-department-of-energy-lab.html
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
October 4 at 1:00 AM  |  Porter & Company (Ad)
Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362137/0/en/q-c-technologies-names-yossef-ehrlichman-chief-technology-officer-to-lead-optical-processor-development.html
Q/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338427/0/en/q-c-technologies-appoints-veteran-silicon-photonics-engineer-yossef-ehrlichman-as-founding-manager-photonic-integrated-circuit-pic-development.html
Q/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference Initiative
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320730/0/en/q-c-technologies-relocates-headquarters-to-san-francisco-in-proximity-to-world-class-engineering-experts-for-photonic-computing-and-optical-ai-inference-initiative.html
See More Mymd Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mymd Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mymd Pharmaceuticals and other key companies, straight to your email.

About Mymd Pharmaceuticals

Mymd Pharmaceuticals (NASDAQ:QCLS) is a clinical-stage biotechnology company focused on developing therapies for diseases associated with aging, chronic inflammation and immune-system dysfunction. Its research has centered on small-molecule drug candidates intended to regulate immune and metabolic pathways.

The company’s lead development program has included MYMD-1, an orally administered investigational compound studied for potential applications involving autoimmune disease, chronic inflammation and age-related conditions. MyMD has also evaluated other therapeutic opportunities related to immunometabolic regulation and cannabidiol-based treatments.

MyMD Pharmaceuticals has primarily operated as a U.S.-based development-stage biotechnology company, with its activities focused on research, preclinical work and clinical development rather than commercialized products. Publicly available information does not provide enough reliable detail to describe current leadership or to confirm the relationship between MyMD Pharmaceuticals and the ticker symbol QCLS.

View Mymd Pharmaceuticals Profile
Earnings Tools